1.A comparative study to evaluate the efficacy and safety of 5% dapsone gel versus 5% benzoyl peroxide gel in Filipino patients with mild to moderate acne vulgaris in a tertiary hospital
Christine Lyka R. Sayson ; Clarisse G. Mendoza ; Evangeline B. Handog ; Bianca Victoria C. Peñ ; a
Journal of the Philippine Dermatological Society 2024;33(Suppl 1):41-41
BACKGROUND
Acne vulgaris is a common skin disorder among adolescents and young adults, with a worldwide prevalence of 9.4%. Both 5% dapsone gel and 5% benzoyl peroxide gel (BPO) have been reported in literature to have antimicrobial action against Cutibacterium acnes.
OBJECTIVETo compare the efficacy and safety of 5% dapsone gel versus 5% BPO gel in Filipino patients with mild to moderate acne vulgaris in a tertiary hospital.
METHODSPhase 1 involved compounding 5% dapsone gel and assessing its safety in healthy individuals through a repeated open application test in 30 participants. In phase 2, a double- blinded experimental study compared the efficacy and safety of both groups. Participants were randomized through block design. Efficacy and safety was assessed using the Global Acne Assessment Score (GAAS) and lesion count, and monitoring the adverse effects. The Cardiff Acne Disability Index (CADI) questionnaire was utilized to evaluate the impact on quality of life.
RESULTSIn phase 1, 56.7% of the participants were female and the only reported adverse event was pruritus (13.3%). In phase 2, both the BPO and dapsone group had 35 participants enrolled. Most are female (75.7%) with a mean age of 24. Results showed improvement in the GAAS from moderate to mild, a decrease in inflammatory and non-inflammatory lesions, and a reduction in side effects during the succeeding visits in both groups.
CONCLUSION5% dapsone gel and 5% BPO were both efficacious and safe for mild to moderate acne management.
Human ; Acne ; Acne Vulgaris ; Dapsone ; Benzoyl Peroxide
2.Mpox in patients seen at the Research Institute for Tropical Medicine: A case series
L. Angelique Gene E. Duran ; Adrian Kevin B. Agonoy ; Christine Lyka R. Sayson ; Emanuel F. Gatdula ; Ara Patricia D. Abeleda ; Lorrie Suzette Urbano-Cruz ; Marie Socouer M. Oblepias ; Mark Kristoffer U. Pasayan
Journal of the Philippine Dermatological Society 2024;33(Suppl 1):14-15
The World Health Organization declared mpox outbreak as a public health emergency of international concern in July 2022 and August 2024. To date, the Philippines has reported 15 confirmed cases. This report described the demographics, clinical presentations, transmission risks, outcome and viral genetic clades of confirmed mpox cases.
Data from six RT-PCR-confirmed cases at the Research Institute for Tropical Medicine identified MPXV clade II in five cases and MPXV clade III in one case. The cases involved five cisgender men who have sex with men (MSM), three of which were known to be people living with HIV (PLHIV) on antiretroviral therapy (ART) and one cisgender female. The median age was 31. Two cases had a history of international travel prior to symptoms.
The cases presented with skin rash (100%), fever (100%), malaise (100%), genital rash (67%), localized lymphadenopathy (16.67%), and headache (16.67%). Skin lesions were umbilicated, presenting as vesicles (100%), papules (83%), or pustules (50%). Secondary bacterial skin infections were reported in two cases. Sequelae included post-inflammatory hyperpigmentation and scarring. No severe complications or deaths occurred.
Mpox outbreak emphasized the threat of emerging and re-emerging infectious diseases. This report provides insights on mpox’ clinical manifestations, transmission, and outcomes in MSM and PLHIV. Mild disease presentations in HIV patients emphasize the importance of ART adherence in preventing severe complications. Despite the small sample size, this study underscores the need for ongoing surveillance and targeted public health intervention focusing on awareness, safe sexual practices, early diagnosis and treatment.
Human ; Hiv ; Mpox ; Mpox, Monkeypox
3.Oral sirolimus in the treatment of adult eruptive cherry angiomas
Christine Lyka R. Sayson, MD ; Aira Monica R. Abella, MD ; Danielle Marlo R. Senador, MD ; Leilani R. Senador, MD, FPDS ; Gisella U. Adasa, MD, FPDS
Journal of the Philippine Dermatological Society 2023;32(1):35-38
Introduction:
Cherry angiomas are a common type of acquired vascular proliferation of the skin which manifest as single or multiple
bright red spots that usually appear on the trunk and arms. They are generally asymptomatic; patients may opt to remove the lesions for
cosmetic reasons and prevention of bleeding. Conventionally, most cherry angiomas are treated with curettage, laser, and electrosurgery. Herein, we report a case of multiple cherry angiomas managed alternatively with oral sirolimus.
Case:
A 47-year-old Filipino female presented with a 10-month history of gradually enlarging multiple bright-red papules and
pedunculated nodules with a propensity to spontaneously bleed on gentle manipulation involving the scalp and forehead. Clinicopathological correlation suggests a diagnosis of eruptive cherry angiomas. The patient was started on oral sirolimus, a mammalian target of
rapamycin (mTOR) inhibitor.
Conclusion
We present a case of a patient with eruptive cherry angiomas who experienced significant decrease in size and bleeding
with treatment of oral sirolimus with minimal adverse effects. For patients with eruptive cherry angiomas, especially with contraindicated
comorbidities, first-line therapeutic option treatments with oral sirolimus can be beneficial.
sirolimus
;
vascular malformation